Acurx Pharmaceuticals, Inc. (ACXP) vs Biomerica, Inc. (BMRA)
A side-by-side comparison of Acurx Pharmaceuticals, Inc. and Biomerica, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ACXP
Acurx Pharmaceuticals, Inc.
$1.31HealthcareDelayed quote: Oct 6, 2026, 9:58 AM EDT
BMRA
Biomerica, Inc.
$2.01HealthcareDelayed quote: Oct 6, 2026, 10:03 AM EDT
Total return — ACXP vs BMRA
growth of $100 · dividends reinvested · last 5yACXP -99.2% (-61.6%/yr)BMRA -93.5% (-42.2%/yr)BMRA compounded faster over this window
Log scale — wide-divergence pair
ACXP BMRA
ACXP vs BMRA: by the numbers
- •BMRA is the larger company ($6M vs $6M market cap).
- •Both run net losses; ACXP's is the smaller (0.00% vs -84.79% net margin).
Metrics side by side
Valuation
| Metric | ACXP | BMRA |
|---|---|---|
| P/S ratio | N/A | 1.40 |
| P/B ratio | 0.69 | 2.36 |
Profitability
| Metric | ACXP | BMRA |
|---|---|---|
| Gross margin | 0.00% | 8.09% |
| Operating margin | 0.00% | -119.54% |
| Net margin | 0.00% | -84.79% |
| ROE | -92.08% | -143.54% |
| ROIC | -94.08% | -117.93% |
Growth (annualized)
| Metric | ACXP | BMRA |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -9.17% |
| Total return CAGR (5Y) | -57.41% | -46.66% |
Frequently asked
- How have ACXP and BMRA total returns compared?
- Over the past 5 years, ACXP delivered -57.41% and BMRA delivered -46.66% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.